Understanding Botox: Its Origins, Medical Uses and Safety

Facial Aesthetics · 11 October 2026

A medical doctor assessing a patient’s frown expression in a modern clinic. — Individual assessment helps guide whether botulinum toxin treatment is appropriate. Illustrative scene with fictional people, not actual Elixir staff or patients.

Botox is one of the best-known names in aesthetic medicine, yet many people are surprised to learn that its story begins with food poisoning, passes through eye surgery and neurology, and only later reaches cosmetic care. Understanding where it came from, how it works and what its limits are can help you have a more informed conversation with your doctor.

What is Botox?

BOTOX® is a brand name for onabotulinumtoxinA, a pharmaceutical preparation of purified botulinum toxin type A. The name “Botox” is a shortened form of “botulinum toxin”.

Several other botulinum toxin type A products are made by different manufacturers. They are not identical, and their dosing units are not interchangeable, so one brand cannot simply be substituted for another unit for unit. Pharmaceutical treatment uses a purified, carefully controlled protein; it does not involve injecting live bacteria.

Where the word “botulinum” comes from

“Botulinum” derives from the Latin “botulus”, meaning sausage. The term reflects early investigations of a serious illness linked to contaminated preserved foods, particularly sausages, in southern Germany.

Historically reconstructed German household scene with preserved sausages on a wooden table. — Ordinary-looking preserved sausages in an early nineteenth-century Württemberg home. Historical reconstruction; contamination cannot be identified by appearance, smell or taste.

A period physician attending a weakened adult patient in a historical sickroom reconstruction. — A reconstructed early nineteenth-century sickroom illustrates medical care during the period of early botulism investigations.

Foodborne botulism is a rare but dangerous illness caused by eating food contaminated with the toxin. It is quite different from an appropriately prescribed pharmaceutical treatment given by a trained clinician. Importantly, contaminated food cannot reliably be identified by its appearance, smell or taste, which is why safe food preparation and preservation matter.

Nineteenth-century discovery

Between 1817 and 1822, the German physician and poet Justinus Kerner published detailed descriptions of patients who had become ill after eating spoiled sausages. He recorded symptoms such as muscle weakness and paralysis, and proposed that the responsible substance acted on the nervous system. Remarkably, he also suggested that it might one day have therapeutic uses.

In 1895, after an outbreak in the Belgian village of Ellezelles linked to preserved ham, the bacteriologist Émile van Ermengem identified the bacterium responsible. His findings were published in 1897. The organism is now known as Clostridium botulinum.

Archival portrait of physician Justinus Kerner in old age. — Justinus Kerner, circa 1860. Photograph by Friedrich Brandseph; public-domain archival image via Wikimedia Commons. This later-life portrait is not dated to his 1817–1822 investigations.

Authentic 1897 archival portrait of Belgian bacteriologist Emile van Ermengem. — Emile van Ermengem, 1897. Portrait by Florimond Van Loo, Ghent University Library; public-domain archival reproduction via Wikimedia Commons.

A fictional nineteenth-century scientist examining a slide with a period microscope. — Generic late nineteenth-century bacteriology scene, a historical reconstruction rather than an archival photograph or a portrait of an identified scientist.

From the laboratory into medicine

The modern medical story is closely associated with the American ophthalmologist Alan B. Scott, who was searching for a non-surgical way to treat strabismus—a condition in which the eyes are not aligned in the same direction.

An illustrative adult portrait showing one eye turned outward while the other faces forward. — Strabismus means the eyes are not aligned in the same direction. This generated illustration is not a patient photograph or a treatment result.

Human clinical investigations began in 1977.
Early clinical results were published in 1980.
In 1989, the product, then called Oculinum, received its first US approval for strabismus and blepharospasm (involuntary eyelid closure).
Allergan acquired the product in 1991, and it was renamed Botox in 1992.

Arriving in cosmetic medicine

While treating eye and facial muscle disorders, clinicians noticed that some patients’ wrinkles softened. Canadian doctors Jean and Alastair Carruthers studied this effect, and their influential 1992 publication described its use for glabellar frown lines between the eyebrows.

Cosmetic clinical use developed over the following decade, before the US Food and Drug Administration (FDA) approved BOTOX Cosmetic in April 2002 for the temporary improvement of moderate to severe glabellar lines.

A compact timeline

1817–1822 — Discovery: Justinus Kerner describes foodborne botulism in detail.
1895–1897 — Discovery: Émile van Ermengem identifies the bacterium and publishes his findings.
1977–1980 — Early clinical use: Alan B. Scott begins human investigations for strabismus and publishes early results.
1989 — Regulatory approval (US): Oculinum is approved for strabismus and blepharospasm.
1992 — Early cosmetic use: The Carruthers publish their work on glabellar lines; the product is renamed Botox.
2002 — Regulatory approval (US): BOTOX Cosmetic is approved for moderate to severe glabellar lines.

Timeline of botulinum toxin discovery, early medical applications and US cosmetic approval. — Discovery, initial clinical investigations and regulatory approval are distinct milestones. US approvals are identified; authorisations vary between countries.(Select to enlarge)

These dates refer to US approvals. Authorisations, approved uses and the products available differ from country to country, and your doctor can explain the status of a particular product where you are being treated.

How it works

Muscles move when motor nerves send them a signal. At the junction between a nerve and a muscle, the nerve ending releases a chemical messenger called acetylcholine, which tells the muscle to contract.

Botulinum toxin type A acts at that nerve ending. The molecule has two main parts: a heavy chain of approximately 100 kDa, which helps it attach to and enter the nerve ending, and a light chain of approximately 50 kDa, which does the work inside. (A kilodalton, or kDa, is simply a unit used to describe the size of a molecule.)

Experimentally derived botulinum neurotoxin type A backbone structure with its light chain, heavy-chain domains, zinc and interchain disulfide bond labelled. — Experimental BoNT/A structure rendered from RCSB PDB 3BTA (Lacy et al., 1998). Light chain is gold; heavy-chain translocation region is teal; heavy-chain binding region is navy. The figure depicts the neurotoxin backbone and selected features, not the complete commercial formulation. Light/heavy masses are approximate.(Select to enlarge)

Inside the nerve ending, the light chain cuts a protein called SNAP-25. This protein is needed for the tiny packages, or vesicles, that contain acetylcholine to fuse with the nerve-cell membrane and release their contents. With SNAP-25 cut, less acetylcholine is released, so the treated muscle contracts less strongly.

Two-panel diagram comparing normal acetylcholine release with reduced release after cleavage of SNAP-25 by botulinum toxin A. — Simplified comparison of normal neurotransmission and reduced acetylcholine release after botulinum toxin A acts at the motor nerve ending. SNAP-25 cleavage impairs vesicle fusion; muscle acetylcholine receptors are not directly blocked. Not to scale.(Select to enlarge)

The effect is temporary. Nerve endings gradually restore their function, and muscle activity returns. For facial lines, results commonly last around three to four months, although this varies from person to person.

Aesthetic applications

In aesthetic medicine, botulinum toxin is used to soften lines caused by repeated muscle movement. Common areas include:

Forehead lines: horizontal lines that appear when you raise your eyebrows.
Frown lines: also called glabellar lines or “11” lines—these terms describe the same area between the eyebrows.
Crow’s feet: lines that fan out from the outer corners of the eyes when smiling.
Vertical platysma bands: cord-like bands in the neck formed by the platysma muscle.
Selected additional uses: such as bunny lines on the nose, a gummy smile caused by muscle activity, and enlarged masseter (jaw) muscles.

Five-panel labelled illustration of common muscle-related facial lines and vertical neck bands. — Forehead lines, frown or glabellar or 11 lines, crow’s feet, bunny lines and vertical platysma bands. Frown, glabellar and 11 lines refer to the same area. Some applications are off-label; suitability and authorisations vary.(Select to enlarge)

Some of these uses are authorised indications for particular products in particular countries; others are off-label, meaning they are used on the basis of clinical judgement rather than a formally approved indication. Suitability and approval status depend on the product, the country and your clinical assessment.

Botulinum toxin works on muscle activity. It does not treat pigmentation, volume loss or substantial skin laxity, which may be better addressed with other treatments.

Medical uses beyond wrinkles

Botulinum toxin also has an established role in medicine. Selected uses include:

Chronic migraine prevention in eligible adults.
Muscle spasticity, such as stiffness after a stroke.
Cervical dystonia, involuntary contractions of the neck muscles.
Blepharospasm and selected cases of strabismus.
Severe underarm sweating (axillary hyperhidrosis).
Selected bladder disorders, such as certain forms of overactive bladder.

Six-panel collage showing clinical care for migraine, spasticity, cervical dystonia, eye disorders, sweating and bladder disorders. — Selected medical uses of botulinum toxin require condition-specific assessment and appropriate specialist care. Illustrative images.(Select to enlarge)

Each of these requires condition-specific assessment by appropriately trained clinicians. Not every person with these conditions is eligible, and treatment helps to manage symptoms rather than cure the underlying condition.

Safety and assessment

Botulinum toxin has been used medically for several decades, and there is extensive clinical experience with it. However, no treatment is risk-free. Safe care depends on a qualified clinician, an authentic pharmaceutical product, an appropriate clinical setting and an individual assessment.

Before treatment, please discuss the following with your doctor:

Allergies, including any previous reaction to a botulinum toxin product.
Infection or inflammation at the proposed treatment site.
All medicines and supplements you take, including blood thinners and certain antibiotics.
Previous botulinum toxin, filler or other aesthetic treatments.
Neuromuscular conditions, such as myasthenia gravis.
Any difficulty swallowing or breathing.
Pregnancy, plans for pregnancy or breastfeeding.

Do not stop any prescribed medicine yourself; your doctor will advise you if any change is needed.

Side effects and complications

Most side effects are mild and temporary, such as discomfort, redness, swelling or bruising at the injection site, and headache.

Sometimes the toxin can weaken nearby muscles that were not intended to be treated. Depending on the area, this may cause eyelid or eyebrow drooping, changes to the smile or other effects. These effects are usually temporary, but they can last for several weeks.

Rare but serious reactions can occur, including severe allergic reactions and effects that spread beyond the injection area.

Seek urgent medical attention if you develop difficulty breathing, swallowing or speaking, or marked generalised weakness after treatment.

If you notice any other unexpected effect, contact your treating clinician so that it can be assessed. Not every unwanted effect can be reversed immediately; some need time to settle as the treatment wears off.

Your consultation at Elixir Clinic

At Elixir Clinic, any recommendation begins with a consultation. Your doctor will consider your concerns, medical history, facial anatomy and expectations before discussing whether botulinum toxin treatment may be appropriate for you.

We will explain the potential benefits and limitations, the alternatives—including choosing not to have treatment—the relevant risks, and the aftercare involved. You will have time to ask questions and to decide in your own time. No treatment is suitable for everyone, and results cannot be guaranteed.